Benefit of "triplet therapy" confirmed with enzalutamide too

[Tall_Allen]

An updated, subgroup analysis of the ENZAMET trial among newly diagnosed men with metastases confirms the triplet of ADT+enzalutamide+docetaxel increases survival. 5 year survival was 60% for the triplet vs 52% for ADT+docetaxel. The benefit was especially pronounced in the first 2 years of triplet therapy in men with high volume metastases.

urotoday.com/conference-hig...

Enzalutamide (Xtandi) joins abiraterone (Zytiga) and darolutamide (Nubeqa) in showing usefulness in triplet therapy added to docetaxel and ADT.

[garyjp9]

thank you, TA

[Farn]

So am I reading this right in that there is no benefit to the triple therapy approach for low volume men if using Enzalutamide ?Thanks for the signpost

[Tall_Allen in reply to Farn]

There is more benefit in high volume men, but there was some benefit in all men.